Effectiveness of BNT162b2 vaccine against SARS-CoV-2 Delta and Omicron infection in adolescents, Norway, August 2021 to January 2022

• DOI: 10.1016/j.ijid.2023.03.004
• Publication Date: 2023-03-08T01:46:10Z
• Authors: Lamprini Veneti; Jacob Dag Berild; Sara Viksmoen Watle; Jostein Starrfelt; Margrethe Greve-I...; Petter Langlete; Håkon Bøås; Karoline Bragstad; Olav Hungnes; Hinta Meijerink
• Keywords: 2019-20 coronavirus outbreak

We estimated the BNT162b2 vaccine effectiveness (VE) against any (symptomatic or not) SARS-CoV-2 Delta and Omicron infection among adolescents (aged 12-17 years) in Norway from August 2021 to January 2022.We used Cox proportional hazard models, where status was included as a time-varying covariate models were adjusted for age, sex, comorbidities, residence county, birth country, living conditions.The VE peaked at 68% (95% confidence interval [CI]: 64-71%) 62% CI: 57-66%) days 21-48 after first dose those aged 12-15 years 16-17 years, respectively. Among who received two doses, 93% 90-95%) 35-62 decreased 84% 76-89%) ≥63 vaccination. did not observe protective effect receiving one dose. 53% 43-62%) 7-34 second 23% 3-40%) vaccination.We found reduced protection doses compared Delta. Effectiveness with time vaccination both variants. The impact of on reducing thus transmission is limited during dominance.